Prevalence of nonsilent mutations in CD70, TMSB4X, B2M, DTX1, UBE2A, and LYN in an extended cohort of DLBCL patients (n = 136).CD70 was the most frequent mutation target in the present cohort. TMSB4X and LYN are novel mutation targets in DLBCL.